Targeted therapy plus chemo vs chemo alone for stage 3 stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests adding disitamab vedotin (a drug that targets HER2) to standard chemotherapy (SOX) after surgery for stage 3 stomach cancer. The goal is to see if the combination works better than chemo alone to prevent cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had surgery to remove your stomach cancer and nearby lymph nodes, and all visible cancer was removed.
- Your cancer was stage 3 at tumor testing and shows moderate to high levels of HER2 (a protein that helps some cancers grow).
- You have not had any cancer treatment before surgery, like chemo or targeted therapy.
- You are in good general health and able to perform daily activities without help (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests whether adding immunotherapy to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It is for people whose cancer has been fully removed and who need further treatment.
This trial tests whether adding immunotherapy to standard chemotherapy after surgery helps prevent stomach or gastroesophageal junction cancer from coming back. It is for people who already had chemotherapy before surgery and have HER2-negative adenocarcinoma.
This trial tests different adjuvant treatments for patients who had stomach or gastroesophageal junction cancer, received chemotherapy with immunotherapy before surgery, and had a complete response (no cancer left) in the surgical sample. It aims to find which treatment works best to prevent the cancer from coming back.
This trial compares two chemotherapy combinations (oxaliplatin plus S-1 vs docetaxel plus S-1) for people with stage III stomach cancer who have had complete surgical removal of the tumor. The goal is to see which combination works better to prevent cancer from returning.
Hear when a new GC/GEJC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.